

AD _____

Award Number: DAMD17-01-1-0523

TITLE: UGT1A9 Genetic Polymorphisms and Raloxifene
Pharmacogenetics

PRINCIPAL INVESTIGATOR: Rebecca B. Raftogianis, Ph.D.

CONTRACTING ORGANIZATION: Fox Chase Cancer Center
Philadelphia, Pennsylvania 19111

REPORT DATE: May 2003

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030902 107

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE May 2003	3. REPORT TYPE AND DATES COVERED Final (1 May 01 - 30 Apr 03)		
4. TITLE AND SUBTITLE UGT1A9 Genetic Polymorphisms and Raloxifene Pharmacogenetics			5. FUNDING NUMBERS DAMD17-01-1-0523	
6. AUTHOR(S) Rebecca B. Raftogianis, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Fox Chase Cancer Center Philadelphia, Pennsylvania 19111 E-Mail: RL_Blanchard@fccc.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) The goal of this DOD Breast Concept award was to identify and functionally characterize common genetic polymorphisms in the human UDP-glucuronosyltransferase gene, UGT1A9. We had previously determined that UGT1A9, a metabolic enzyme expressed predominantly in the human liver, catalyzes the glucuronidation and inactivation of the antiestrogen raloxifene (RAL). The pharmacokinetics of RAL is known to be subject to significant interindividual variation, possibly associated with variable clinical efficacy. We hypothesized that genetic variation in the human UGT1A9 gene contributed to the known variation in RAL pharmacokinetics in humans. The aims of this proposal were to 1) identify genetic polymorphisms within the coding regions of the human UGT1A9 gene, 2) functionally characterize recombinant UGT1A9 allozymes with regard to capacity to glucuronidate RAL and 3) express variant UGT1A9 cDNAs in MCF-7 cells and assess antiestrogenic response of cells to RAL.				
14. SUBJECT TERMS UDP-glucuronosyltransferase 1A9; pharmacogenetics; Raloxifene			15. NUMBER OF PAGES 7	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover..... 1

SF 298 2

Introduction..... 4

Body..... 4

Key Research Accomplishments..... 5

Reportable Outcomes..... 7

Conclusions 7

References..... N/A

Bibliography of Publications..... N/A

List of Personnel..... 7

Appendices..... N/A

INTRODUCTION

The goal of this DOD Breast Concept award was to identify and functionally characterize common genetic polymorphisms in the human UDP-glucuronosyltransferase gene, UGT1A9. We had previously determined that UGT1A9, a metabolic enzyme expressed predominantly in the human liver, catalyzes the glucuronidation and inactivation of the antiestrogen raloxifene (RAL). The pharmacokinetics of RAL is known to be subject to significant interindividual variation, possibly associated with variable clinical efficacy. We hypothesized that genetic variation in the human UGT1A9 gene contributed to the known variation in RAL pharmacokinetics in humans. The aims of this proposal were to 1) identify genetic polymorphisms within the coding regions of the human UGT1A9 gene, 2) functionally characterize recombinant UGT1A9 allozymes with regard to capacity to glucuronidate RAL and 3) express variant UGT1A9 cDNAs in MCF-7 cells and assess antiestrogenic response of cells to RAL.

BODY

Aim 1. Identify common genetic polymorphisms in the human UGT1A9 gene. The UGT1A9 gene is part of a nested UGT1A gene family on human chromosome 2. The organization of this locus is such that alternative transcription initiation occurs at promoters of eight unique first exons, followed by splicing to common exons 2 through 5. Thus, eight unique UGT1A isoforms are expressed from this locus and those proteins differ in sequence at the amino terminal 530 amino acids by virtue of the unique exon 1 and they each share identical carboxy-terminal protein sequence that is encoded by the common exons 2 through 5. We and others have previously shown a lack of variation in gene sequence within the shared exons 2 through 5. Thus, genetic variation in UGT1A genes lies predominantly in the unique first exon. Therefore, we initially characterized common genetic variation in the UGT1A9-specific first exon.

Last year, we reported the identification of genetic polymorphisms within the 5' flanking region and 3' intron of UGT1A9. Table 1 describes those polymorphisms as well as their frequencies. Polymorphic loci were in genetic linkage such that different permutations of those polymorphisms defined eight apparent alleles. Of particular interest was the dT 9 or 10 variable length nucleotide repeat (VLNR) in the 5' flanking region of the gene. This position maps to the putative TATAA box of the UGT1A9 promoter.

Specific Aims 2 and 3. Functional Characterization of the UGT1A9 polymorphisms. Our original aims were to functionally characterize polymorphic UGT1A9 proteins (allozymes). However, none of the polymorphisms that we identified altered the encoded amino acid sequence of the protein. Therefore the experiments proposed would not be appropriate. Alternatively, we plan to evaluate the functional significance of the promoter polymorphism by comparing transcriptional activity of reporter constructs driven by the polymorphic promoter and by evaluating the correlation between level of

UGT1A9 transcript and genotype in cell culture systems. Progress on the latter aims has been hampered by a turnover in personnel and therefore an extension to this grant has been requested.

KEY RESEARCH ACCOMPLISHMENTS

- ☐ Identified five common genetic polymorphisms in the 5' flanking region and first intron of the human UGT1A9 gene.
- ☐ Determined the frequency and linkage of each of those polymorphisms in a population of 65 healthy Caucasian Americans.
- ☐ Currently evaluating the functional significance of the VLNR in the putative promoter.

Table 1. Genetic Variation in the Human UGT1A9 Gene

<u>UGT1A9 Variable Loci</u>	<u>Nucleotide Polymorphism</u>	<u>Frequency</u>
- 118 poly dT	T ₉	0.56
	T ₁₀	0.44
- 87	G	0.98
	A	0.02
I1 152	G	0.75
	A	0.25
I1 219	T	0.59
	A	0.41
I1 313	C	0.56
	A	0.44

-118 and -87 refer to nucleotide positions upstream of the "A" in the ATG start codon. I1 refers to intron 1 and the number following the "I1" designation refers to the nucleotide position downstream of the exon/intron junction.

REPORTABLE OUTCOMES

Jeffrey Zalatoris, Ph.D. and Rebecca Blanchard Raftogianis, Ph.D., UDP-glucuronosyltransferase-specific glucuronidation inactivates 4-hydroxytamoxifen and raloxifene. Oral Presentation at 2002 DOD Breast Cancer Era of Hope Meeting in Orlando, Fla.

CONCLUSIONS

We set out to characterize common genetic polymorphisms in the human UGT1A9 gene. Surprisingly, no polymorphisms affecting encoded amino acid sequence were identified. However, five common polymorphisms were identified in 5' flanking and intron regions of the gene. Of particular interest is the variable length nucleotide repeat in the putative promoter region of the gene. We are currently testing the hypothesis that this polymorphism is of functional consequence. Genetically determined variation in UGT1A9 activity may be an important factor in the clinical response of individuals to drugs that are metabolized via this pathway. This study has contributed toward our knowledge of common genetic variation in the human UGT1A9 gene.

REFERENCES

None

BIBLIOGRAPHY OF PUBLICATIONS

None

LIST OF PERSONNEL PAID FROM GRANT

Stephen Beauparant, Postdoctoral Associate
Amanda Thistle, Scientific Technician